tbuckley/cabot-search huggingface dataset:
Cardiac Stress Test Trends Among US Patients Younger Than 65 Years, 2005-2012
Authors: Vinay Kini, Fenton H. McCarthy, Elias Dayoub, Steven M. Bradley, Frederick A. Masoudi, P. Michael Ho, Peter W. Groeneveld
Journal: JAMA Cardiology (2016)

After a period of rapid growth, use of cardiac stress testing has recently decreased among Medicare beneficiaries and in a large integrated health system. However, it is not known whether declines in cardiac stress testing are universal or are confined to certain populations.To determine trends in rates of cardiac stress testing among a large and diverse cohort of commercially insured patients.A serial cross-sectional study with time trends was conducted using administrative claims from all members aged 25 to 64 years belonging to a large, national managed care company from January 1, 2005, to December 31, 2012. Linear trends in rates were determined using negative binomial regression models with procedure count as the dependent variable, calendar quarter as the key independent variable, and the size of the population as a logged offset term. Data analysis was performed from January 1, 2005, to December 31, 2012.Age- and sex-adjusted rates of cardiac stress tests per calendar quarter (reported as number of tests per 100 000 person-years).A total of 2 085 591 cardiac stress tests were performed among 32 921 838 persons (mean [SD] age, 43.2 [10.9] years; 16 625 528 women [50.5%] and 16 296 310 [49.5%] men; 7 604 945 nonwhite [23.1%]). There was a 3.0% increase in rates of cardiac stress testing from 2005 (3486 tests; 95% CI, 3458-3514) to 2012 (3589 tests; 95% CI, 3559-3619; P = .01 for linear trend). Use of nuclear single-photon emission computed tomography decreased by 14.9% from 2005 (1907 tests; 95% CI, 1888-1926) to 2012 (1623 tests; 95% CI, 1603-1643; P = .03). Use of stress echocardiography increased by 27.8% from 2005 (709 tests; 95% CI, 697-721) to 2012 (906 tests; 95% CI, 894 to 920; P < .001). Use of exercise electrocardiography increased by 12.5% from 2005 (861 tests; 95% CI, 847-873) to 2012 (969 tests; 95% CI, 953-985; P < .001). Use of other stress testing modalities increased 65.5% from 2006 (55 tests; 95% CI, 51-59) to 2012 (91 tests; 95% CI, 87-95; P < .001). For individuals aged 25 to 34 years, rates of cardiac stress testing increased 59.1% from 2005 (543 tests; 95% CI, 532-554) to 2012 (864 tests; 95% CI, 852-876; P < .001). For individuals aged 55 to 64 years, rates of cardiac stress testing decreased by 12.3% from 2005 (7894 tests; 95% CI, 7820-7968) to 2012 (6923 tests; 95% CI, 6853-6993; P < .001).In contrast to declines in the use of cardiac stress testing in some health care systems, we observed a small increase in its use among a nationally representative cohort of commercially insured patients. Our findings suggest that observed trends in the use of cardiac stress testing may have been driven more by unique characteristics of populations and health systems than national efforts to reduce the overuse of testing.
An Open-Label, Phase I Study of Dasatinib in Combination with Decitabine in Patients (Pts) with Accelerated or Blastic Phase Chronic Myeloid Leukemia (CML)
Authors: Yasmin Abaza, Hagop M Kantarjian, Gautam Borthakur, Naval Daver, Farhad Ravandi, Dai Chihara, Srdan Verstovsek, Jan A Burger, Zeev Estrov, Maro Ohanian, Elias Jabbour, Jorge E. Cortes
Journal: Blood (2015)
Bone Marrow Cell Aggregates: A Way of Collecting the Adult Human Hematopoietic Stem Cell Niche
Authors: Alexandre Janel, Nathalie Boiret-Dupré, Juliette Berger, Céline Bourgne, Richard Lemal, Frédérique Dubois-Galopin, Pierre Déchelotte, Pierre Verrelle, Eric Hermet, Jacques-Olivier Bay, Marc G Berger
Journal: Blood (2014)
Frequency, Characteristics and Prognostic Significance of RUNX1 mutations in Patients with Acute Myeloid Leukemia, Not Otherwise Specified
Authors: Mi-Hyun Bae, Young-Uk Cho, Bohyun Kim, Dong Hyun Lee, Seongsoo Jang, Eul-Ju Seo, Chan-Jeoung Park, Dae-Young Kim, Jung-Hee Lee, Je-Hwan Lee, Kyoo-Hyung Lee, Yoon Hwan Chang, In-Suk Kim
Journal: Blood (2015)
Acquisition of TP53 Mutations in Chronic Lymphocytic Leukemia (CLL) Patients During the Course of Disease Is Associated with an Unmutated IGHV Status and Mutations in XPO1 and SF3B1
Authors: Vera Grossmann, Alexander Kohlmann, Susanne Schnittger, Sandra Weissmann, Frank Dicker, Sabine Jeromin, Lucia Boeck, Tamara Alpermann, Wolfgang Kern, Torsten Haferlach, Claudia Haferlach
Journal: Blood (2012)
FRI0243 Is The BMP Antagonist Gremlin-1 A Target in Systemic Sclerosis?
Authors: S. O'Reilly
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Gremlin-1 is BMP antagonist that mediates its effects through negative regulation of BMP signalling. BMP signalling is important in development and has been found to be deregulated in various rheumatic diseases. It also has BMP-independant effects that are poorley described. Systemic sclerosis is an autoimmune disease that results in fibrosis of the skin and internal organs. We have previously found elevated levels of gremlin-1 in systemic sclerosis skin biopsies compared to controls. Gremlin-1 genetically reduced mice are protected from kidney fibrosis. It is suggested that fibrosis may be associated with reactivation of development programs. <h3>Objectives</h3> The aim of this work was to measure the levels of gremlin-1 and to determine its effects on dermal fibroblasts. <h3>Methods</h3> Skin biopsies were taken from systemic sclerosis patients and analysed by PCR for gremlin-1 and 18S as the housekeeing gene. Bleomycin was injected into mice and skin fibrosis developed, control mice received saline. Biopsies were taken and fixed and processed. Laser capture was used to dissect the tissue using a guided laser. Dissected tissue was processed for RNA and qPCR was performed for gremlin-1 and collagen-1. C-Myc tagged human Gremlin-1 was cloned into a vector and empty vector was transfected into human fibroblasts and HEKs. After transfection collagen and alpha-Smooth muscle actin was measured. <h3>Results</h3> Elevated levels of gremlin-1 was found in systemic sclerosis skin biopsies. We also found elevated levels of gremlin-1 in skin sections from an animal model of fibrosis, the bleomycin model. Laser capture microdissection found that this was in the dermal proportion of skin and not in the epithelial section. Overexpression of gremlin-1 in a vector system in dermal fibroblasts showed elevated levels of collagen, but not alpha-smooth muscle actin. <h3>Conclusions</h3> Gremlin-1 is dsyregulated in systemic sclerosis and in the bleomycin model of fibrosis. Overexpressing gremlin-1 induced higher levels of collagen. Targeting gremlin-1 may represent a novel target in systemic sclerosis. <h3>Disclosure of Interest</h3> None declared
Diabetes Mellitus Compromises Survival of Young Non Hodgkin Lmphoma Patients Treated with (R) CHOP Chemotherapy - a Retrospective Multicenter Analysis by Polish Lymphoma Study Group
Authors: Wojciech Jurczak, Joanna E Drozd-Sokolowska, Monika Joks, Justyna Dzietczenia, Tomasz Wrobel, Beata Kumiega, Jan Maciej Zaucha, Wanda Knopinska-Posluszny, Wojciech Spychalowicz, Agnieszka Giza, Maciej J Machaczka, Aleksander Skotnicki
Journal: Blood (2012)
Risks of duloxetine for stress incontinence outweigh benefits, say researchers
Authors: Barbara Kermode-Scott
Journal: BMJ (2016)

The antidepressant duloxetine should not be used to treat stress urinary incontinence in women because the harms outweigh the benefits, authors of a new analysis have said.

Although duloxetine reduced the symptoms of stress urinary incontinence and improved women’s quality of life, the harms related to suicidality and violence were 4 to 5 times more common with duloxetine than with a placebo, a meta analysis using patient level data by researchers from the Nordic Cochrane Centre showed.1

The researchers from Rigshospitalet in Copenhagen made their comments after conducting a meta-analysis using clinical study reports submitted to the European Medicines Agency for regulatory approval of duloxetine for stress urinary incontinence in women. They first gained access to clinical study …
AB0459 Tuberculosis among Systemic Lupus Erythematosus Mexican Mestizo Patients
Authors: I.J. Colunga-Pedraza, R.I. Arvizu, A. Martínez-Moreno, D.O. Treviño-Montes, D.A. Galarza-Delgado, M.A. Garza-Elizondo
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Tuberculosis (TB) represents a major global health problem. TB has a higher incidence among patients with autoimmune rheumatic diseases than in the general population. The incidence and severity of TB in patients with systemic lupus erythematosus (SLE) varies greatly among different series (2.5–13.8%). <h3>Objectives</h3> To investigate the frequency and characteristics of TB in Mexican mestizo patients with SLE. <h3>Methods</h3> We reviewed the charts of 123 patients with SLE in our lupus clinic. Patients who developed TB after the diagnosis of SLE were identified. Data of all SLE patients followed up in our clinic were retrospectively analyzed. Clinical and demographic characteristics and treatment before diagnosis of TB were recorded. <h3>Results</h3> A total of 123 SLE patients were analyzed, 89.43% (n=110) woman. Seven cases (5.69%) of TB infection developed after the diagnosis of SLE. Pulmonary TB was reported in 3 patients (2.44%). Extra-pulmonary TB infecction was reported in 3 (2.44%) patients (one case of tuberculous pleurisy, one case of meningeal TB, and 1 case of cutaneous TB). Also, we found 1 SLE patient (0.81%) with latent TB infection. All patients had good response to treatment. No one received biologic therapy at the time of the diagnosis of TB infection. We did not found any case of disseminated infection or mortality related to TB infection. <h3>Conclusions</h3> These results suggest that in a country with high TB burden, TB screening and treatment of latent TB would be useful since the diagnosis of SLE is made. <h3>References</h3> Erdozain, J. G., Ruiz-Irastorza, G., Egurbide, M. V., Martinez-Berriotxoa, A., &amp; Aguirre, C. (2006). High risk of tuberculosis in systemic lupus erythematosus? Lupus, 15(4), 232–235. <h3>Disclosure of Interest</h3> None declared
Treated Multiple Myeloma Patients: Demographic Characteristics, Incidence Rate and Mortality in Lombardy during the 2003-2009 Period
Authors: Paolo Corradini, Alessandro Corso, Lorenzo Giovanni Mantovani, Monica Galli, Anna Maria Cafro, Roberta Ciampichini, Paolo Cozzolino, Virginio Chiodini, Claudia Crippa, Giuseppe Rossi, Giancarlo Cesana, Enrica Morra
Journal: Blood (2014)
FRI0605 Effect of An Educational Intervention Based on Clinical Simulation in The Diagnosis of Spondyloarthritis (SPA) from General Practitioners, A Study before and after
Authors: S.A. Mora Alfonso, D.G. Fernández Άvila, L.F. Sastre
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> This paper wants to quantify the rate of improvement in the diagnosis of SPA among a group of general practitioners who receive an educational intervention based on clinical simulation in the rheumatology field <h3>Methods</h3> Intervention study before and after <h3>Results</h3> 102 general practitioners received an educational intervention based on clinical simulation. The topic of this educational intervention was Spondyloarthritis. A workshop that includes clinical simulation models of feet, fingers and a mannequin created for this purpose was created, based on the strategy of problem-based learning. The workshop lasted 5 hours, it was divided into two parts: the first was about the of the clinical approach of joint pain and lumbar pain diagnosis and relevant aspects of SPA. In this first part, besides the theoretical support for the diagnosis of SPA, participants viewed pictures of patients with spondylitis and peripheral involvement (enthesitis, dactylitis, arthritis) seeking to achieve awareness of their sense of sight with respect to the diagnostic approach to patients with suspected SPA and sought to strengthen the logical approach to be implemented when approaching this type of patients. The second part focused on clinical cases applied to clinical simulation models, applying the knowledge acquired during the theoretical phase. Participants made a several stations where they where they could appreciate for periods of 15 minutes each simulators of 3 feet, 6 simulators simulated fingers and a mannequin where they can identify entheses and psoriasis lesions, improving visual and tactile sensitivity in each semilogic findings for tehe diagnosis of SPA. The participants filled out an pre and post test, which included clinical cases with simulators and photographs of hands and feet of patients with suspected EAS. 102 participants (59% women), average age 32.3 years (SD 7.1). Improvement in the correct diagnosis of EAS of 47% (the correct diagnosis increased from 39% to 86%). Paraclinical application in the cases presented decreased significantly, from an average of 8–4 paraclinical requested by each clinical case presented. 98.5% of participants would recommend to other colleagues to make this workshop. 97.7% believe that this educational intervention will improve the diagnostic approach to patients with suspected SPA <h3>Conclusions</h3> The usefulness of clinical simulation in the field of rheumatology has been shown, given by an improvement in the diagnostic sensitivity for the diagnosis of EAS demonstrated <h3>Disclosure of Interest</h3> None declared
Interpretation and Use of Another Statin Guideline
Authors: Philip Greenland, Robert O. Bonow
Journal: JAMA Cardiology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Functional and regulatory profiling of energy metabolism in fission yeast
Authors: Michal Malecki, Danny A. Bitton, Maria Rodríguez-López, Charalampos Rallis, Noelia Garcia Calavia, Graeme C. Smith, Jürg Bähler
Journal: Genome biology (2016)

The control of energy metabolism is fundamental for cell growth and function and anomalies in it are implicated in complex diseases and ageing. Metabolism in yeast cells can be manipulated by supplying different carbon sources: yeast grown on glucose rapidly proliferates by fermentation, analogous to tumour cells growing by aerobic glycolysis, whereas on non-fermentable carbon sources metabolism shifts towards respiration.We screened deletion libraries of fission yeast to identify over 200 genes required for respiratory growth. Growth media and auxotrophic mutants strongly influenced respiratory metabolism. Most genes uncovered in the mutant screens have not been implicated in respiration in budding yeast. We applied gene-expression profiling approaches to compare steady-state fermentative and respiratory growth and to analyse the dynamic adaptation to respiratory growth. The transcript levels of most genes functioning in energy metabolism pathways are coherently tuned, reflecting anticipated differences in metabolic flows between fermenting and respiring cells. We show that acetyl-CoA synthase, rather than citrate lyase, is essential for acetyl-CoA synthesis in fission yeast. We also investigated the transcriptional response to mitochondrial damage by genetic or chemical perturbations, defining a retrograde response that involves the concerted regulation of distinct groups of nuclear genes that may avert harm from mitochondrial malfunction.This study provides a rich framework of the genetic and regulatory basis of energy metabolism in fission yeast and beyond, and it pinpoints weaknesses of commonly used auxotroph mutants for investigating metabolism. As a model for cellular energy regulation, fission yeast provides an attractive and complementary system to budding yeast.
A Phase II Open-Label, Ac220 Monotherapy Efficacy Study In Patients with Refractory/Relapsed Flt3-Itd Positive Acute Myeloid Leukemia: Updated Interim Results
Authors: Jorge E. Cortes, Alexander E Perl, Catherine C. Smith, Tibor Kovacsovics, Herve Dombret, Hartmut Dohner, Bjorn Steffen, Arnaud Pigneux, Philippe Rousselot, Juergen Krauter, Giovanni Martinelli, Elihu H. Estey, Alan K Burnett, Anthony D. Ho, Norbert Ifrah, Theo de Witt, Robert Corringham, Joyce James, David Lilienfeld, Eugen Leo, Guy Gammon, Mark J. Levis
Journal: Blood (2011)
Ablation of the Duodenal Mucosa as a Strategy for Glycemic Control in Type 2 Diabetes: Role of Nutrient Signaling or Simple Weight Loss
Authors: W. Timothy Garvey
Journal: Diabetes Care (2016)

As our understanding of the pathophysiology of type 2 diabetes (T2D) has advanced, new oral and injectable medications have been developed that target a growing number of the pathophysiological processes that cause hyperglycemia. In addition, weight-loss therapy, involving lifestyle interventions, antiobesity medications, or bariatric surgery, has been demonstrated to be highly effective in T2D management. The expanded number of treatment options has provided an increased capacity for glycemic control. Even so, T2D remains a progressive disease, requiring the intensification of therapy over time, and many patients still do not achieve HbA1c targets. Therefore, new therapeutic strategies for effective and safe glycemic control are critically needed.

In this issue of Diabetes Care , Rajagopalan et al. (1) present a new therapeutic strategy for treatment of T2D. The strong point of the study is that the authors have developed and studied a novel therapeutic approach in T2D that could elucidate new disease mechanisms involving the role of the duodenum in metabolic regulation. The authors present a 6-month interim analysis of a phase I, single-arm, nonrandomized cohort study assessing safety and efficacy of endoscopic duodenal mucosal resurfacing (DMR) for treatment of T2D. This is a first-in-human experience with this intervention, which ablates the duodenal mucosa between the ampulla of Vater and the ligament of Treitz in a two-step endoscopic procedure. First, a catheter with a terminal balloon is passed into the duodenum that has three needles spaced at 120° around the balloon’s circumference. The needles are used to inject saline into the submucosal space in order to circumferentially separate and lift the mucosa from underlying tissues in the duodenal wall. A second catheter then introduces another balloon that thermally ablates (i.e., burns) the lifted mucosa at a temperature of ∼90°C (194°F).

The conceptual basis of the procedure is derived from observations that …
P0085 : Hepatic encephalopathy: Cerebrospinal fluid metabolomics highlights alteration of multiple metabolic pathways representing new potential therapeutic targets
Authors: N. Weiss, F. Isnard, S. Attala, B. Colsch, M. del Mar Amador, F. Lamari, M. Rudler, F. Sedel, C. Junot, D. Thabut
Journal: Journal of Hepatology (2015)
Identifying High-Risk Chronic Lymphocytic Leukemia: A Reappraisal of the Impact of Prognostic and Predictive Factors
Authors: Sara Martinelli, Maurizio Cavallari, Luca Formigaro, Enrico Lista, Olga Sofritti, Giulia Daghia, Maria Ciccone, Francesco Cavazzini, Gian Matteo Rigolin, Antonio Cuneo
Journal: Blood (2015)
SAT0175 Validation of B Cell Depletion as A Predictor of Clinical Response and Efficacy of Retreatment of Non-Response in Rheumatoid Arthritis: Table 1.
Authors: M.Y. Md Yusof, J.B. Candelier, S. Dass, A. Rawstron, E.M. Vital, P. Emery
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rituximab has been licensed for the treatment of Rheumatoid Arthritis (RA) for over a decade. We previously showed that the initial depth of B cell depletion was associated with clinical response; 96% complete versus 74% incomplete depletion at 6 months (p=0.02)[1] and that retreatment of initial non-responders with incomplete depletion led to 72% response rate in cycle 2 (C2)[2]. <h3>Objectives</h3> To validate B cell depletion after the first infusion as a predictor of response to rituximab (Project 1) and assess outcome of retreatment of first cycle non-responders (Project 2) as a basis for B cell monitoring during rituximab treatment. <h3>Methods</h3> The published discovery cohorts included 60 patients in Project 1 and 25 patients in Project 2. For this validation study, we analysed the subsequent consecutive 180 patients with RA treated with rituximab at a single centre. Each cycle of rituximab consisted of 2×1000mg infusions, repeated on clinical relapse. B cell subsets (naïve, memory and plasmablast) were measured at baseline, after first infusion of rituximab (2 weeks) and at early B cell repopulation (6 months) using a flow cytometry protocol optimized to detect low numbers of B cell subsets and plasmablasts. Complete depletion was defined as total B cell count &lt;0.0001×10<sup>9</sup>/L. First cycle non-responders who had incomplete depletion at C1 were retreated at 6 months. <h3>Results</h3> 180 patients (female=147 (81%), median age at rituximab initiation 62 (IQR 51–71) years and median disease duration 10 (IQR 5–18) years were studied. 72 (40%) patients were biologic-naïve. In C1, 126 (70%) achieved moderate-good EULAR response. The complete depletion rate for C1 was 54%. Complete depletion was associated with response; p=0.027 (Table 1). 30 patients who were C1 non-responders and had incomplete depletion were retreated at 6 months. Of these, 20 (67%) had complete depletion and 20 (67%) responded in C2. Non-responders in C2 had trend to higher plasmablast numbers at retreatment than responders (p=0.14). <h3>Conclusions</h3> We have validated that the depth of B cell depletion after the first infusion is a predictor of response to rituximab in RA. A high degree of response in C2 was also confirmed when C1 non-responders who had incomplete depletion were retreated. B cell subsets therefore should be monitored in the routine care of RA patients receiving rituximab and repeat infusions considered if early depletion is incomplete and clinical response poor. <h3>References</h3> Dass S et al. A&amp;R 2008 Vital EM et al. A&amp;R 2010 <h3>Disclosure of Interest</h3> None declared
Low Dose Azacitidine Maintenance Therapy Following Allogeneic Stem Cell Transplantation for MDS/AML Does Not Interact with Tacrolimus Dosing or Serum Levels
Authors: Hans C. Lee, Joshua Howell, Denái Milton, Sergio A Giralt, Julianne J Chen, Gabriela Rondon, Richard E. Champlin, Simrit Parmar, Marcos De Lima
Journal: Blood (2012)
Diagnosing Myasthenia Gravis with an Ice Pack
Authors: Wendy W Liu, Adam Chen
Journal: New England Journal of Medicine (2016)

A 68-year-old man presented with unilateral ptosis. Neurologic examination revealed ptosis of the left eye after a sustained upward gaze. Myasthenia gravis was suspected, and an ice-pack test was performed with an instant cold pack over the left eye.
Comparison of Imatinib, Dasatinib, Nilotinib and INNO-406 in Imatinib-Resistant Cell Lines.
Authors: Shinya Kimura, Yasuyuki Deguchi, Eishi Ashihara, Tomoko Niwa, Keoko Hodohara, Yoshihide Fujiyama, Taira Maekawa
Journal: Blood (2007)